Key Highlights

  • FY27 Revenue guidance is A$19 million to A$20 million, compared with A$16.8 million reported for FY26.
  • EBITDA guidance is A$1.0 million to A$1.5 million, compared with a FY26 EBITDA loss of A$0.92 million.
  • The company has set a three-year target of A$50 million in annual revenue.
  • A program of about A$7 million is underway to upgrade sterile and oral dose Manufacturing capabilities.

IDT Australia Limited (ASX:IDT) has provided full-year guidance for FY27, forecasting revenue and Earnings before interest, tax, Depreciation and Amortisation to rise materially from the prior year. The Boronia, Victoria-based pharmaceutical manufacturer, which provides contract development and manufacturing services for high potency and high containment products, attributed the outlook to a strategic reset initiated early in FY26 and to committed client contracts expected to begin in the second half of FY27.

FY27 Guidance Against FY26 Results

The company forecasts revenue from its three operating verticals of A$19 million to A$20 million, an increase of 13 to 19 % on FY26 revenue of A$16.8 million. EBITDA is guided to between A$1.0 million and A$1.5 million, compared with a loss of A$0.92 million in FY26, implying an improvement of A$1.9 million to A$2.4 million.

Executive Chair Mark Simari said the growth uplift is being driven by a higher-quality customer base, larger programs and more diversified revenue streams. The company said the reset has also been aimed at reducing revenue lumpiness, which it described as inherent in the contract manufacturing sector, by building a deeper Backlog of projects across all three verticals.

Customer Mix and the Three-Year Target

IDT said it has increasingly prioritised engagement with larger pharmaceutical and biotech groups able to support longer-term development and manufacturing programs, while continuing to serve emerging biotech clients. The company has secured a further five-year contract with an existing radiopharmaceutical client, and it described a deepening relationship with Sanofi, which it said may open opportunities beyond Research and Development work.

IDT has set a target of A$50 million in annual revenue within three years. The company linked that ambition to new market expansion, deeper client relationships and growing Demand for specialist contract development and manufacturing services. It cited a global sterile injectables CDMO market valued at US$41.6 billion in 2026, forecast to grow at a compound annual rate of 11.2 %, with Asia-Pacific expected to grow at 12.3 %.

Facility Investment

Underpinning the three-year target is an Investment of about A$7 million to modernise facilities and upgrade capabilities in specialty oral and sterile manufacturing. The company said the investment has already contributed to the five-year radiopharmaceutical contract, and that it expects the upgrade to support its ability to secure larger, higher-value contracts. The facilities are cGMP compliant and are regularly audited by the US Food and Drug Administration and the Australian Therapeutic Goods Administration, according to the company.

Final Perspective

The guidance sets out a path from an EBITDA loss in FY26 to a modest profit in FY27, with the largest contribution expected from contracts starting in the second half. Whether the company reaches its A$50 million target will depend on the conversion of its pipeline and the completion of its Facility upgrade. Further reporting on contract timing and revenue recognition is expected to provide a clearer picture of progress against the guidance.